Table 1.
Patient demographics and disease characteristics at baseline
| Parameter | Value (N = 50) |
|---|---|
| Mean age (range), years |
69.3 (44–91) |
| Men,% |
58 |
| Race/ethnicity,% |
|
| White |
86.0 |
| Black/African American |
8.0 |
| Asian |
2.0 |
| Pacific Islander |
2.0 |
| Other |
2.0 |
| Mean body mass index (SD), kg/m2 |
25.0 (4.37) |
| Myelofibrosis subtype,% |
|
| PMF |
62.0 |
| PPV-MF |
30.0 |
| PET-MF |
8.0 |
| DIPSS risk category,% |
|
| High |
20.0 |
| Intermediate-2 |
62.0 |
| Intermediate-1 |
18.0 |
| ECOG status,% |
|
| 0 |
12.0 |
| 1 |
74.0 |
| 2 |
12.0 |
| Missing |
2.0 |
| History of transfusion in 12 weeks before baseline,% |
40.0 |
| Previous HU use,% |
44.0 |
| Mean platelet count (SD), × 109/L |
72.1 (21.9) |
| Mean hemoglobin (SD), g/L |
97.3 (15.7) |
| Mean WBC (SD), × 109/L |
19.6 (20.2) |
| Mean TSS (SD) |
19.4 (11.8) |
| Mean spleen length (SD), cm |
13.4 (7.2) |
| Mean spleen volume (SD), cm3 | 2387.3 (1527.3) |
Samples will be analyzed for JAK2V617F status at the end of study.
DIPSS, Dynamic International Prognostic Scoring System; ECOG, Eastern Cooperative Oncology Group; HU, hydroxyurea; JAK, Janus kinase; PET-MF, post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; PPV-MF, post-polycythemia vera myelofibrosis; SD, standard deviation; TSS, Total Symptom Score; WBC, white blood cell.